Empagliflozin & Type 2 diabetes (T2D)

Background

Empagliflozin has shown rapid absorption reaching peak levels in ~2 hours and an elimination half-life of ~13 hours. It is a highly selective SGLT2 inhibitor with 2600-fold higher affinity for SGLT2 compared with SGLT1. Oral administration results in a dose-dependent inhibition of the transporters with increased urinary glucose excretion and resultant reduction in plasma glucose. Its efficacy and safety have been shown in a number of studies conducted in many countries. Across the trials, significant improvements in primary and secondary efficacy end points have been demonstrated, including reductions in HbA 1c, fasting plasma glucose, body weight, and blood pressure (systolic ‑4 mmHg and diastolic ‑2 mmHg). Simi…